2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-118311
    (Z)-W 3699 63250-48-6 98%
    (Z)-W 3699 is a potential choleretic. (Z)-W 3699 can increase the solubility of cholesterol in the gallbladder by altering the secretion of micellar bile acids. (Z)-W 3699 can prevent the formation of cholesterol-containing gallstones in dogs.
    (Z)-W 3699
  • HY-118334
    Armillaramide 111149-09-8 98%
    Armillaramide (Desulfated ircisulfamide) is an ester product.
    Armillaramide
  • HY-118358
    C8 L-threo ceramide (d18:1/8:0) 175892-44-1 98%
    C8 L-threo ceramide (d18:1/8:0) (N-Octanoyl-L-threo-sphingosine) is an ester product.
    C8 L-threo ceramide (d18:1/8:0)
  • HY-118364
    AGN 190727 115503-91-8 98%
    AGN 190727 is a structural isomer of AGN 190121 and has no activating effect on RAR/RXR. AGN 190121 is a RAR-specific agonist that causes a dose-dependent increase in serum triglycerides, leading to hypertriglyceridemia.
    AGN 190727
  • HY-118367
    A 80915A 127875-60-9 98%
    A 80915A is a seminaphthoquinone produced by Streptomyces and is a potent inhibitor of Na+/K+ ATPase involved in gastric acid secretion.
    A 80915A
  • HY-118492
    Riodipine 71653-63-9 98%
    Riodipine (PP-1466) is a vasodilator. Riodipine can be used for the research of antihypertensive.
    Riodipine
  • HY-118514
    CAY10514 868526-38-9 98%
    CAY10514 is an aromatic of 8(S)-HETE. CAY10514 acts as a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ with IC50 of 0.173 and 0.642 μM, respectively.
    CAY10514
  • HY-118665
    L-736380 152885-49-9 98%
    L-736380 is a high affinity CCK-B (cholecystokinin B receptor) receptor antagonist, with IC50 values of 0.054 nM and 400 nM for CCK-B and CCK-A, respectively. L-736380 dose-dependently inhibits gastric acid secretion in anesthetized rats (ID50, 0.064 mg/kg) and ex vivo binding of [125I]CCK-8S in BKTO mice brain membranes (ED50, 1.7 mg/kg).
    L-736380
  • HY-118788
    N-Desmethyl rosiglitazone 257892-31-2 98%
    N-Desmethyl rosiglitazone (SB 237216) is a metabolite of Rosiglitazone (HY-17386), generated through demethylation by the cytochrome P450 enzyme system in liver microsomes. It retains partial PPARγ agonist activity and supports studies on the metabolism and pharmacokinetics of Rosiglitazone (HY-17386).
    N-Desmethyl rosiglitazone
  • HY-118821
    JTC-017 357330-77-9 98%
    JTC-017, a specific corticotropin-releasing hormone receptor 1 antagonist, attenuates hippocampal noradrenaline release, visceral perception, adrenocorticotropic hormone release, and anxiety after acute colorectal distention in rats. JTC-017 blocks stress-induced changes in colonic motility after chronic colorectal distention in rats.
    JTC-017
  • HY-118904
    VL-0395 620167-11-5 98%
    VL-0395 is a CCK1 selective antagonist with IC50 of 0.197 μM for CCK1 in rat pancreatic acinar cells.
    VL-0395
  • HY-118934
    Novocebrin 36702-84-8 98%
    Novocebrin is a central nervous system activator that effectively increases brain and femoral blood flow in dogs. In addition, Novocebrin inhibits triglyceride biosynthesis in porcine adipose tissue.
    Novocebrin
  • HY-119127
    TP-680 176915-07-4 98%
    TP-680 is a cholecystokinin receptor antagonist. TP-680 binds 1510 times more strongly to rat pancreatic CCKA receptors (IC50=1.2 nM) than to rat brain CCKB receptors (IC50=1812.5 nM). TP-680 can be used in the study of gastrointestinal diseases.
    TP-680
  • HY-119197
    PPARα/γ/δ agonist 1 853652-40-1 98%
    PPARα/γ/δ agonist 1 (Compound 2) is a potent PPARα/γ/δ agonist, with an IC50 of 70 nM for PPARγ. PPARα/γ/δ agonist 1 can be used for the research of type 2 diabetes.
    PPARα/γ/δ agonist 1
  • HY-119203
    NNC 38-1049 757183-18-9 99.84%
    NNC 38-1049 is an orally active, potent and competitive histamine H3 receptor antagonist. NNC 38-1049 produced an increase in extracellular levels of histamine in the paraventricular nucleus. NNC 38-1049 decreases food intake and body weight, which is promising for research of obesity.
    NNC 38-1049
  • HY-119220
    Granotapide 594842-13-4 98%
    Granotapide (JTT-130) is an orally active microsomal triglyceride transfer protein (MTP) inhibitor. Granotapide reduces absorption of cholesterol and triglycerides through inhibition of MTP. Granotapide can be used for the research of dyslipidemia.
    Granotapide
  • HY-119265
    LDL-IN-4 615264-62-5 98%
    LDL-IN-4 (Compound 2) inhibits human acyl-CoA:cholesterol acyltransferase-1 and -2 activities. LDL-IN-4 inhibits copper-mediated low density lipoprotein (LDL) oxidation, with an IC50 of 3 μM. LDL-IN-4 has anti-atherosclerotic biological activity.
    LDL-IN-4
  • HY-119311
    Ketopioglitazone 146062-45-5 98%
    Pioglitazone ketone is an active metabolite of the PPARγ agonist Pioglitazone (HY-13956). Formation of pioglitazone ketone occurs primarly through cytochrome P450 (CYP) isoform CYP2C8-mediated metabolism of pioglitazone. Pioglitazone ketone (100 mg/kg in the diet) reduces blood glucose levels in a KKAy mouse model of type 2 diabetes.
    Ketopioglitazone
  • HY-119497
    SB251023 208842-53-9 98%
    SB251023 is a β3-adrenergic receptor agonist with pEC50 values of 7.14 and 6.91 for the β3a- and β3b-adrenergic receptors, respectively. SB251023 is capable of modulating cyclic AMP levels and extracellular acidification rate (EAR) in cells. It has potential application value in the study of cardiovascular diseases and metabolic-related disorders.
    SB251023
  • HY-119741
    Salacinol 200399-47-9 98%
    Salacinol can be isolated from the roots of the plant Salacia reticulata. Salacinol inhibits fat metabolizing enzymes, such as pancreatic lipase (PL, IC50=12.6 mg/L), lipoprotein lipase (LPL, IC50=13.6 mg/L), and glycerophosphate dehydrogenase (GPDH), enhances the lipolysis, and exhibits antiobesity efficacy in rats.
    Salacinol
Cat. No. Product Name / Synonyms Application Reactivity